Browse > Article

Comparison of Single-Dose Toxicity by Intravenous Infusion or Bolus Injection with CKD-602, a Camptothecin Anticancer Agent in Rats (II): Hematological and Serum Biochemical, and Histopathological Changes  

Kim, Choong-Yong (Korea Institute of Toxicology, KRICT)
Yang, Byung-Chul (Korea Institute of Toxicology, KRICT)
Kim, Joon-Kyum (Medicinal Research Center, Chong Kun Dang Co.)
Kim, Jong-Choon (College of Veterinary Medicine, Chonnam National University)
Kim, Yong-Beom (Korea Institute of Toxicology, KRICT)
Kang, Boo-Hyon (Korea Institute of Toxicology, KRICT)
Han, Sang-Seop (Korea Institute of Toxicology, KRICT)
Publication Information
Toxicological Research / v.20, no.4, 2004 , pp. 381-389 More about this Journal
Abstract
The toxicity of CKD-602 was investigated at doses of 3, 9, and 27 mg/kg in rats, when the same total dose of CKD-602 was administered over 24 hr-continuous infusion or bolus injection. At 3 and 9 mg/kg, the 24-hr infusion group showed a more decreased WBC count on day 3, compared with the bolus group. Administration of CKD-602 caused more toxic effects such as the significant decreases of RBC counts, hematocrit, hemoglobin, and platelet count on day 7 post-administarion in the 24-hr infusion group than in the bolus group. Administration of CKD-602 also caused histopathological changes such as extramedullary hemopoiesis of liver and spleen, hyperplasia of femoral bone marrow, and caecal dilation. These toxic effects were more severe in the 24-hr infusion group than in the bolus injection group, indicating that the toxicity of CKD-602 may be dependant upon the duration of administration.
Keywords
CKD-602; Infusion; Toxicity; Rat;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bleiberg, H. and Rothenberg, M.L. (1996): CPT-11: From DNA topology to clinical activity. Semi. Oncol., 23, 1-50
2 Bozec, L., Bierling, P, Fromont, P, Levi, F., Debat, P, Cvitkovic, E. and Misset, J.L. (1998): Irinotecan-induced immune thrombocytopenia. Ann. Oncol., 9, 453-455
3 Cass, I., Kuo, D.Y., Fields, AL., Runowicz, C.D. and Goldberg, G.L. (1998): Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. Gynecol. Oncol., 69, 175-178
4 Dahut, W, Harolod, N., Takimototo, C., Allegra, C., Chen, A, Hamilton, J.M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, Wand Grem, J. (1996): Phase I and pharmacokinetic study of 9aminocamptothecin given as a 72-hour infusion in adult cancer patients. J. Glin. Oncol., 14, 1236-1244
5 Edelman, E.R. and Karnovsky, M.J. (1994): Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation, 89, 770-776   DOI   PUBMED
6 Kasahara, K., Nishikawa, A., Furukawa, F., Ikezaki, S., Tanakamaru, Z., Lee, I.S., Imazawa, T. and Hirose, (2002): A chronic toxicity study of josamycin in F344 rats. Food Chem. Toxicol., 40, 1017-1022.
7 Kim, C.Y., Imai, Y, Ito, K., Hashimoto, J., Nobunaga, T., Satoh, H. and Abe, K. (1996): Analysis of circadian variation of blood pressure and heart rate in dexamethasoneinduced hypertensive rats. Clin. Exper. Hypertension, 18, 65-76
8 Kolimannsberger, C., Mross, K., Jakob, A, Kanz, L. and Bokemyer, C. (1999): Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology, 56, 1-12   DOI   ScienceOn
9 Thompson, J., Stewart, C.F. and Houghton, P.J. (1998): Animal models for studyinq the action of topoisomerase I targeted drugs. Biochim. Biophys Acta, 1400, 301-319
10 Toti, P., De Felice, C., Stumpo, M., Schrfeld, K., Di Leo, L., Vatti, R., Bianciardi, G., Buonocore, G., Seemayer, TA and Luzi, P. (2000): Acute thymic involution in fetuses and neonates with chorioamnionitis. Hum. Pathol., 31, 1121-1128
11 Wall, ME, Wani, M.C. and Cook, C.E. (1966): Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88, 3888-3890   DOI
12 Lee, J.H., Lee, J.M., Kim, J.K., Ahn, S.K., Lee, S.J., Kim, M.Y., Jew, S.S., Park, J.G. and Hong, C.I. (1998): Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)- camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res., 21, 581-590.
13 Evans, J.G. and Kerry, P.J. (2000): Common pathological findings in continuous infusion studies. In: Guy healing and David Smith (eds.) Handbook of preclinical continuous intravenous infusion. Taylor & Francis, pp 253-264
14 Gottlieb, J.A., Guarino, A.M., Call, J.B., Oliverio, V.T. and Block, J.B. (1970): Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep., 54, 461-470
15 Fujitani, T., Tada, Y and Yoneyama, M. (2004): Chlorpropham-induced splenotoxicity and its recovery in rats. Food Chem. Toxicol., 42, 1469-1477
16 Hertzberg, R.P., Caranfa, M.J., Holden, K.G., Jakas, D.R., Gallagher, G., Mattern, M.R., Mong, S.M., Bartus, J.O., Johnson, R.K. and Kingsbury, WD. (1989): Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32, 715-720   DOI   PUBMED
17 Flynn, J.L., Chan, J., Triebold, K.J., Dalton, O.K., Stewart, T.A. and Bloom, B.R. (1993): An essential role for interferon gamma in resistance to mycobacterium tuberculosis infection. Journal of Experimental Medicine, 178, 2249-2254   DOI
18 Tomas, F.M., Lemmey, A.B., Read, L.C. and Ballard, F.J. (1996): Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J. of Endocrinology, 150, 77-84   DOI   ScienceOn
19 Greaves, P. (2000): Digestive system I, In: Histopathology of preclinical toxicity studies ($2^{nd}$ eds) Elsevier Science, pp. 398-401
20 Jung, L.L. and Zamboni, WC. (2001): Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it ? Drug. Resistance Updates, 4, 273-288
21 Takimoto, C.H., Wright, J. and Arbuck, S.G. (1998): Clinical applications of the camptothecins. Biochirn. Biophys. Acta, 1400,107-119
22 Pizzolato, J.F. and Saltz, L.B. (2003): The camptothecins. Lancet, 361, 2235-2242
23 Gargosky, S.E., Tapanainen, P. and Rosenfeld, R.G. (1994): Administration of growth hormone (GH), but not insulinlike growth factor-I (IGF-I), by continuous infection can induced the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats. Endocrinology, 134, 2267-2276   DOI   PUBMED   ScienceOn
24 Rothenberg, M.L. (1997): Topoisomerase I inhibitors: review and update. Ann. Oncol., 8, 837-855
25 Slichenmyer, WJ. and Rowinsky, E.K. (1993): The current status of amptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85, 271-291   DOI   PUBMED
26 Moertel, C.G., Schutt, AJ., Reitmeier, R.J. and Hahn, R.G. (1972): Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56, 95-101